Somewhat Positive Press Coverage Somewhat Unlikely to Impact Maximus (MMS) Stock Price

Media stories about Maximus (NYSE:MMS) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Maximus earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the health services provider an impact score of 45.8991211622529 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

Shares of Maximus stock opened at $70.73 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57. Maximus has a twelve month low of $58.43 and a twelve month high of $72.71. The firm has a market cap of $4,527.15, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.40 and a beta of 1.12.

Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, February 8th. The health services provider reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.01. The company had revenue of $623.10 million during the quarter, compared to analysts’ expectations of $624.36 million. Maximus had a net margin of 8.99% and a return on equity of 22.93%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.71 EPS. sell-side analysts expect that Maximus will post 3.31 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 31st. Shareholders of record on Tuesday, May 15th will be given a $0.045 dividend. The ex-dividend date is Monday, May 14th. This represents a $0.18 dividend on an annualized basis and a yield of 0.25%. Maximus’s payout ratio is currently 5.94%.

A number of brokerages recently weighed in on MMS. Zacks Investment Research cut shares of Maximus from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. Canaccord Genuity decreased their price target on shares of Maximus from $71.00 to $65.00 and set a “hold” rating for the company in a research report on Friday, February 9th. Finally, Maxim Group reaffirmed a “hold” rating and set a $69.00 price target (up from $66.00) on shares of Maximus in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the stock. Maximus has a consensus rating of “Hold” and an average price target of $66.60.

In other Maximus news, General Counsel David Francis sold 3,600 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $64.50, for a total value of $232,200.00. Following the completion of the transaction, the general counsel now directly owns 10,017 shares of the company’s stock, valued at approximately $646,096.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Russell A. Beliveau sold 1,000 shares of the company’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $66.55, for a total transaction of $66,550.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,600 shares of company stock valued at $3,009,650. 2.48% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/19/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-maximus-mms-stock-price.html.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.

Insider Buying and Selling by Quarter for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply